Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS. Schönfeld K, et al. Among authors: kloess s. Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6. Mol Ther. 2015. PMID: 25373520 Free PMC article.
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
Munkelt D, Koehl U, Kloess S, Zimmermann SY, Kalaäoui RE, Wehner S, Schwabe D, Lehrnbecher T, Schubert R, Kreuter J, Klingebiel T, Esser R. Munkelt D, et al. Among authors: kloess s. Cancer Chemother Pharmacol. 2008 Oct;62(5):821-30. doi: 10.1007/s00280-007-0669-3. Epub 2008 Feb 2. Cancer Chemother Pharmacol. 2008. PMID: 18246351
IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, Koenig M, Erben S, Seidl C, Tonn T, Eggert A, Schramm A, Bader P, Klingebiel T, Lehrnbecher T, Passweg JR, Soerensen J, Schwabe D, Koehl U. Huenecke S, et al. Among authors: kloess s. J Immunother. 2010 Feb-Mar;33(2):200-10. doi: 10.1097/CJI.0b013e3181bb46f7. J Immunother. 2010. PMID: 20145545 Clinical Trial.
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS. Esser R, et al. Among authors: kloess s. J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x. J Cell Mol Med. 2012. PMID: 21595822 Free PMC article.
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol.
Koehl U, Brehm C, Huenecke S, Zimmermann SY, Kloess S, Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S, Wunram C, Gardlowski T, Auth E, Tonn T, Seidl C, Meyer-Monard S, Stern M, Passweg J, Klingebiel T, Bader P, Schwabe D, Esser R. Koehl U, et al. Among authors: kloess s. Front Oncol. 2013 May 17;3:118. doi: 10.3389/fonc.2013.00118. eCollection 2013. Front Oncol. 2013. PMID: 23730623 Free PMC article.
Advantages and applications of CAR-expressing natural killer cells.
Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U. Glienke W, et al. Among authors: kloess s. Front Pharmacol. 2015 Feb 12;6:21. doi: 10.3389/fphar.2015.00021. eCollection 2015. Front Pharmacol. 2015. PMID: 25729364 Free PMC article. Review.
Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation.
Sundarasetty BS, Kloess S, Oberschmidt O, Naundorf S, Kuehlcke K, Daenthanasanmak A, Gerasch L, Figueiredo C, Blasczyk R, Ruggiero E, Fronza R, Schmidt M, von Kalle C, Rothe M, Ganser A, Koehl U, Stripecke R. Sundarasetty BS, et al. Among authors: kloess s. J Transl Med. 2015 Jul 22;13:240. doi: 10.1186/s12967-015-0599-5. J Transl Med. 2015. PMID: 26198406 Free PMC article.
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.
Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von Strandmann E. Vyas M, et al. Among authors: kloess s. Oncoimmunology. 2016 Jul 15;5(9):e1211220. doi: 10.1080/2162402X.2016.1211220. eCollection 2016. Oncoimmunology. 2016. PMID: 27757305 Free PMC article.
28 results